Relay Therapeutics, Inc. (RLAY) Tops Q3 EPS by 14c

Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q3 EPS of ($0.63), $0.14 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $0 versus the consensus estimate of $88.89 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.

You May Also Be Interested In

• FDA accepts Teva's drug application for Tourette syndrome therapy in children
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
• Cosmos Health posts 29% revenue gain in Q2 but widens net loss